Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the re-filing of its Abbr...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday b...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio assumes NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announce...
US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in p...
